Hansa Biopharma Year-end report January-December 2023 : vima

/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...

Related Keywords

Germany , Sweden , Stockholm , Slovenia , United States , Italy , Spain , Hansa Biopharma , Klaus Sindahl , Hitto Kaufmann , Medison Pharma , Matthew Shaulis , Prnewswire Hansa Biopharma , Donato Spota , Stephanie Kenney , Eurotransplant Desensitization Program , Newbridge Pharmaceuticals , Acceptable Mismatch Program , Vp Global Corporate Affairs , Desensitization Program , Duchenne Muscular Dystrophy , Middle East , North Africa , Eastern European , Crigler Najjar Phase , Annual Report , Interim Report , General Meeting , Half Year Report January , Friday February , Securities Markets , Nasdaq Stockholm , Hansa Biopharma Ab ,